Moderna COVID-19 Shot Is 93% Effective After Six Months Of Second Dose

Moderna COVID-19 Shot Is 93% Effective After Six Months Of Second Dose
  • Moderna Inc's MRNA COVID-19 vaccine continues to be 93% effective six months after the second dose, the Company reported in its Q2 earnings release.
  • The number shows that efficacy "remains durable" through that time and hardly wanes from the 94.5% efficacy Moderna reported last November. 
  • By comparison, Pfizer Inc PFE and BioNTech SE BNTX said their vaccine efficacy declined to around 84% after six months.
  • "We are pleased that our COVID-19 vaccine is showing durable efficacy of 93% through six months, but recognize that the Delta variant is a significant new threat, so we must remain vigilant," Moderna CEO Stéphane Bancel said.
  • Moderna said that candidates who received a booster shot during a phase 2 trial produced "robust antibody responses" against the Delta and Gamma variants.
  • "Given this intersection, we believe dose 3 booster will likely be necessary before the winter season," Moderna wrote, per CNBC.
  • Bancel said that the Company is working to create "a single dose annual booster" that protects adults against the virus, the flu, and the respiratory syncytial virus.
  • Related: Moderna Sold Less Than Expected mRNA COVID-19 Vaccine Jabs In Q2; Sees $20B In FY21 Product Sales.
  • Price Action: MRNA shares are down 1.34% at $413.67 during the market session on the last check Thursday.
  • Image by Spencer Davis from Pixabay

Posted In: BriefsCOVID-19 VaccineBiotechNewsHealth CareMoversTrading IdeasGeneral